Recent advances in the design of mechanism-based (or suicide) and transition state inhibitors for serine proteases, along with the resolution of the crystal structure of thrombin, now makes it possible to pioneer a new generation of clinically useful antithrombotic agents. The long term goal of this research is the design, synthesis, and testing of potent new low molecular weight antithrombotic agents suitable for clinical use in humans in situations where heparin and aspirin are ineffective. Although there are several classes of antithrombotic drugs currently in use, none prevent reocclusion of some diseased arteries cleared by thrombolysis or the occlusive complications associated with surgical management of patients with vascular diseases. Clearly there is a need for more effective antithrombotic drugs. Thrombin and the enzymes which produce thrombin are serine proteases with trypsin-like specificity. Thrombin has a critical role in the activation of platelets during the formation of arterial thrombus in addition to mediating fibrin-rich thrombus formation. Small molecular weight thrombin inhibitors will abolish the formation of arterial thrombi, a process that is resistant to heparin. Thus, mechanism-based and transition-state inhibitors for thrombin or the enzymes which generate thrombin are likely to be clinically useful anticoagulants. Mechanism-based and transition state inhibitors have the advantage of being potent, specific for the target enzyme, unreactive with other proteins and thus non-toxic. The recent resolution of the x-ray structure of thrombin presents the opportunity for solving the structures of thrombin-inhibitor complexes and using computer-aided molecular modeling in the design of new more potent inhibitor structures for thrombin. The inhibitors synthesized in this research will be tested for 1) in vitro potency and specificity using purified coagulation serine proteases, 2) stability in plasma, 3) ability to inhibit complexes of coagulation proteases with their natural cofactors, and 4) efficacy in small animal models. The inhibitors produced in this research will be potentially useful for therapy and their study by kinetic analysis, x-ray diffraction analysis, in vitro coagulation tests, and in vivo testing will provide important new insights into thrombogenesis and the hemostatic mechanism.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL034035-05
Application #
3346583
Study Section
Bio-Organic and Natural Products Chemistry Study Section (BNP)
Project Start
1987-04-01
Project End
1995-06-30
Budget Start
1992-07-01
Budget End
1993-06-30
Support Year
5
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Georgia Institute of Technology
Department
Type
Schools of Arts and Sciences
DUNS #
097394084
City
Atlanta
State
GA
Country
United States
Zip Code
30332
Kerrigan, J E; Powers, J C; VanDerveer, D (1996) 4-Chloro-7-(iodoacetyl)amino-3-methoxy-isocoumarin. Acta Crystallogr C 52 ( Pt 2):451-3
Kam, C M; Hernandez, M A; Patil, G S et al. (1995) Mammalian tissue trypsin-like enzymes: substrate specificity and inhibitory potency of substituted isocoumarin mechanism-based inhibitors, benzamidine derivatives, and arginine fluoroalkyl ketone transition-state inhibitors. Arch Biochem Biophys 316:808-14
Powers, J C; Kam, C M (1995) Peptide thioester substrates for serine peptidases and metalloendopeptidases. Methods Enzymol 248:3-18
Kerrigan, J E; Oleksyszyn, J; Kam, C M et al. (1995) Mechanism-based isocoumarin inhibitors for human leukocyte elastase. Effect of the 7-amino substituent and 3-alkoxy group in 3-alkoxy-7-amino-4-chloroisocoumarins on inhibitory potency. J Med Chem 38:544-52
Brown, A D; Powers, J C (1995) Rates of thrombin acylation and deacylation upon reaction with low molecular weight acylating agents, carbamylating agents and carbonylating agents. Bioorg Med Chem 3:1091-7
Oleksyszyn, J; Powers, J C (1994) Amino acid and peptide phosphonate derivatives as specific inhibitors of serine peptidases. Methods Enzymol 244:423-41
Powers, J C; Kam, C M (1994) Isocoumarin inhibitors of serine peptidases. Methods Enzymol 244:442-57
Kam, C M; Kerrigan, J E; Plaskon, R R et al. (1994) Mechanism-based isocoumarin inhibitors for blood coagulation serine proteases. Effect of the 7-substituent in 7-amino-4-chloro-3-(isothioureidoalkoxy)isocoumarins on inhibitory and anticoagulant potency. J Med Chem 37:1298-306
Powers, J C; Odake, S; Oleksyszyn, J et al. (1993) Proteases--structures, mechanism and inhibitors. Agents Actions Suppl 42:3-18
Dolman, K M; van de Wiel, B A; Kam, C M et al. (1993) Proteinase 3: substrate specificity and possible pathogenetic effect of Wegener's granulomatosis autoantibodies (c-ANCA) by dysregulation of the enzyme. Adv Exp Med Biol 336:55-60

Showing the most recent 10 out of 22 publications